Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Accenture
QuintilesIMS
Argus Health
McKinsey
Merck
Cipla
Harvard Business School
Federal Trade Commission

Generated: August 17, 2018

DrugPatentWatch Database Preview

Bayer Healthcare Llc Company Profile

« Back to Dashboard

What is the competitive landscape for BAYER HEALTHCARE LLC, and when can generic versions of BAYER HEALTHCARE LLC drugs launch?

BAYER HEALTHCARE LLC has twenty-seven approved drugs.

There is one US patent protecting BAYER HEALTHCARE LLC drugs.

There are thirty-one patent family members on BAYER HEALTHCARE LLC drugs in twenty-eight countries and six supplementary protection certificates in three countries.

Summary for Bayer Healthcare Llc
International Patents:31
US Patents:1
Tradenames:21
Ingredients:11
NDAs:27
Patent Litigation for Bayer Healthcare Llc: See patent lawsuits for Bayer Healthcare Llc

Drugs and US Patents for Bayer Healthcare Llc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Healthcare Llc GYNE-LOTRIMIN clotrimazole CREAM;VAGINAL 018052-002 Nov 30, 1990 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial
Bayer Healthcare Llc CHLOR-TRIMETON chlorpheniramine maleate; pseudoephedrine sulfate TABLET, EXTENDED RELEASE;ORAL 018397-001 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial
Bayer Healthcare Llc MYCELEX-7 COMBINATION PACK clotrimazole CREAM, TABLET;TOPICAL, VAGINAL 020389-002 Jun 23, 1994 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Bayer Healthcare Llc CLARITIN-D loratadine; pseudoephedrine sulfate TABLET, EXTENDED RELEASE;ORAL 019670-002 Nov 27, 2002 OTC Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Bayer Healthcare Llc GYNE-LOTRIMIN clotrimazole TABLET;VAGINAL 017717-002 Nov 30, 1990 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial
Bayer Healthcare Llc CHLOR-TRIMETON chlorpheniramine maleate TABLET, EXTENDED RELEASE;ORAL 007638-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Bayer Healthcare Llc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bayer Healthcare Llc MYCELEX clotrimazole CREAM;TOPICAL 018183-001 Approved Prior to Jan 1, 1982 3,705,172 ➤ Try a Free Trial
Bayer Healthcare Llc CLARITIN loratadine TABLET;ORAL 019658-002 Nov 27, 2002 4,659,716*PED ➤ Try a Free Trial
Bayer Healthcare Llc CLARITIN-D 24 HOUR loratadine; pseudoephedrine sulfate TABLET, EXTENDED RELEASE;ORAL 020470-002 Nov 27, 2002 4,863,931*PED ➤ Try a Free Trial
Bayer Healthcare Llc CLARITIN loratadine SYRUP;ORAL 020641-002 Nov 27, 2002 6,132,758 ➤ Try a Free Trial
Bayer Healthcare Llc ZEGERID OTC omeprazole; sodium bicarbonate CAPSULE;ORAL 022281-001 Dec 1, 2009 6,489,346 ➤ Try a Free Trial
Bayer Healthcare Llc CLARITIN loratadine SYRUP;ORAL 020641-002 Nov 27, 2002 4,863,931*PED ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for BAYER HEALTHCARE LLC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Capsules 20 mg/1100 mg ➤ Subscribe 2010-04-20

Non-Orange Book US Patents for Bayer Healthcare Llc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,514,520 Stabilized antihistamine syrup ➤ Try a Free Trial
6,939,550 Stabilized antihistamine syrup ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

International Patents for Bayer Healthcare Llc Drugs

Country Document Number Estimated Expiration
Guatemala 199900072 ➤ Try a Free Trial
New Zealand 508037 ➤ Try a Free Trial
European Patent Office 1082117 ➤ Try a Free Trial
Colombia 5011119 ➤ Try a Free Trial
Gulf Cooperation Council 0000330 ➤ Try a Free Trial
Serbia 49609 ➤ Try a Free Trial
Country Document Number Estimated Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for Bayer Healthcare Llc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB11/013 United Kingdom ➤ Try a Free Trial PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
C0004 France ➤ Try a Free Trial PRODUCT NAME: DESLORATADINE; PSEUDOEPHEDRINE SULFATE; REGISTRATION NO/DATE: EU/1/07/399/001 20070730
C/GB01/012 United Kingdom ➤ Try a Free Trial PRODUCT NAME: DESLORATADINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/00/157/001-013 20010115; UK EU/1/00/158/001-013 20010115; UK EU/1/00/159/001-013 20010115; UK EU/1/00/160/001-013 20010115; UK EU/1/00/161/001-013 20010115
01C/013 Belgium ➤ Try a Free Trial PRODUCT NAME: DESLORATADINE; REGISTRTION NO/DATE: EU/1/00/160/010 20010115
C/GB08/005 United Kingdom ➤ Try a Free Trial SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/005 GRANTED TO MERCK SHARP + DOHME CORP. IN RESPECT OF THE PRODUCT DESLORATADINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN COMBINATION WITH PSEUDOEPHEDRINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6322 DATED 21 JULY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 JULY 2022.
C/GB11/015 United Kingdom ➤ Try a Free Trial PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Citi
Covington
Healthtrust
Harvard Business School
QuintilesIMS
McKesson
Deloitte
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.